Law & Policy

Rolling the dice on eligibility

Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications

Rolling the dice on eligibility
14 Feb 2019

As 101 debate continues, Iancu offers clear message to Federal Circuit

With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent

13 Feb 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco 

Latest

View all
11 Feb 2019

Huawei owns the future and that’s why it’s here to stay

Deep pockets, a strong commitment to R&D and a world class 5G patent portfolio mean that whatever its current difficulties the Chinese telecoms business is set to be a major player for the long term Read more

9 Feb 2019

The big life sciences patent developments in January

Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more Read more

8 Feb 2019

US patent system jumps to second in the world, though the biopharma sector may not agree

PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies Read more

5 Feb 2019

USPTO rules on patent term adjustment set to change following CAFC decision

The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences Read more

News

View all
1 Feb 2019

We have not been informed of any Chinese antitrust investigation of us, Ericsson tells IAM

Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway Read more

31 Jan 2019

Pressure piles on US pharma and biotech IP owners

America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely    Read more

23 Jan 2019

Kokes hails "fantastic first year" as NantWorks CIPO

In exclusive interview with IAM, after confirming as a speaker for IPBC Global 2019, the former BlackBerry IP chief talks in-depth about life sciences and high tech convergence - and the many patent opportunities that creates  Read more

23 Jan 2019

Welcome to the future of patents

New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond Read more

Analysis

View all
28 Jan 2019

Critical condition: has Section 101 put the US medical device sector on life support?

As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies Read more

25 Jan 2019

New preliminary injunction rules set stage for Apple's showdown with Qualcomm

New rules on preliminary injunctions from the Supreme People's Court could have a significant affect on IP litigation in China – not least the long-running battle between Apple and Qualcomm. Read more

25 Jan 2019

SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration Read more

25 Jan 2019

Treat IP rights as property to maximise their value, Huawei CEO urges

In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead Read more

Insights

View all
30 Nov 2018

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative. Read more

27 Sep 2018

A Brexit IP issue with serious political consequences

The UPC and EU trademarks will not inflame any Brexit passions among those outside the IP bubble, but geographical indications are a different matter altogether Read more

1 Jun 2018

Supreme Court shakes up the PTAB, while new USPTO head sends strong pro-patent signals

No one expected the Supreme Court to turn the US patent system upside down with Oil States – and it did not. But its SAS judgment issued on the same day could mean some big post-grant changes. Meanwhile, Andrei Iancu is exhibiting pro-patent inclinations Read more

1 Feb 2018

Rollercoaster ride for SEP owners continues through 2017

SEP owners had much to celebrate in 2017 but a major decision from a US court meant that the year ended with a familiar amount of uncertainty Read more

Find an expert

W Todd Baker
Partner
Alexandria VA, United States
Oblon